All clinical trials come with inherent challenges. Sponsors must navigate an intricate web of regulatory issues, approval time frames, operational complexities, and perhaps the greatest hurdle – patient recruitment and retention. These predictable challenges are compounded exponentially in global clinical trials due to their scope.

Whether you’re attending the J.P. Morgan Healthcare Conference, BioWeekSF, or any other conference, chances are you’re preparing to present to some of the industry’s most renowned investors.  Are you prepared for the pitch? 

In this 3-episode series, President, CEO, and Founder of Amygdala Neurosciences,  Peter Strumph, discusses his journey to secure funding for his substance abuse therapy. What made him so successful? Listen now to find out.

Get better patient participation, site and physician engagement, and global scale.

The advances in our understanding of pain mechanisms and a large number of clinical studies have not translated into more effective, affordable, and safer pharmaceutical products. But we can change that.. Read on to learn more about our experience in these clinical trials.

Our 40 year tradition of clinical trial excellence is centered on Alzheimer’s Disease. Unparalleled experience in this indication (including related dementias) enables us to thoroughly understand the complexities in evaluating patients with various phenotypes, and to implement specific study design features in Alzheimer’s disease clinical trials that mitigate risks and challenges.